Clinical Trial: The Effect of Therapy With Bevacizumab in Chronic Central Serous Chorioretinopathy

Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Intraocular Concentrations of Growth Factors and Cytokines in Chronic Central Serous Chorioretinopathy And the Effect of Therapy With Bevacizumab

Brief Summary: The pathophysiology of central serous chorioretinopathy remains controversial. traditional treatment is laser photocoagulation or photodynamic therapy.Recently Bevacizumab (Avastin, Genetech),an antibody to vascular endothelial growth factor (VEGF),has known antipermeability properties and therefore may theoretically reverse the changes seen in central serous chorioretinopathy. The aim of this study is To investigate concentrations of growth factors and inflammatory cytokines and to report the effect of therapy with bevacizumab in eyes with central serous chorioretinopathy

Detailed Summary:
Sponsor: Hallym University Medical Center

Current Primary Outcome: Concentrations of growth factors and inflammatory cytokines in Aqueous humor [ Time Frame: at baseline ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Central macular thickness at optical coherence tomography [ Time Frame: baseline, 1 month, 3 months, 6 months ]

Original Secondary Outcome: Same as current

Information By: Hallym University Medical Center

Dates:
Date Received: March 18, 2009
Date Started: March 2009
Date Completion: March 2010
Last Updated: March 18, 2009
Last Verified: March 2009